United States of America — Federal officials will host a series of listening sessions this summer to examine high prescription drug costs and competitive barriers in the pharmaceutical industry. The effort is part of implementing President Trump’s Executive Order No. 14273, Lowering Drug Prices by Once Again Putting Americans First.
The Federal Trade Commission and Department of Justice are leading the initiative, with support from the Department of Health and Human Services and the Department of Commerce. The sessions will focus on expanding access to generics and biosimilars, addressing regulatory abuse, and identifying ways to improve competition and reduce costs.
The first session will take place Monday, June 30 at 2 p.m., followed by additional sessions on July 24 and August 4. Topics include patent settlements, restricted distribution, pharmacy benefit practices, Orange Book listings, and market access challenges.
While in-person attendance is by invitation only, all sessions will be livestreamed online. Members of the public may submit questions in advance and access the livestream and session materials through ftc.gov. After each event, video recordings and transcripts will be made available on the same site.
The discussions will inform a joint federal report on curbing anticompetitive practices in drug markets. Public input is encouraged and may be used in the final report. Personal information submitted through the FTC’s online platform is subject to FOIA and federal privacy rules.
